H.C. Wainwright Reiterates Buy Rating on Cardiol Therapeutics (CRDL)

October 24, 2024 7:44 AM EDT Send to a Friend
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $9.00 price target on Cardiol Therapeutics (NASDAQ: CRDL).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login